NorthWest Biotherapeutics Inc (NWBO)

[gpb]

Whole lysate antigen is the concept underpinning dcvax-l, selected antigen-mimicking peptide is the concept underpinning ict-107. So when the author says:
"DCs were collected via leukapheresis and were pulsed either with autologous whole tumor lysate or with the glioma-associated peptide antigens gp100, TRP2, her2, and survivin."
You can read that as:
'DCs were prepared similar to DCVax-L or similar to ICT-107'

Then when he says:
"overall survival in the whole tumor–pulsed lysate group is significantly improved compared to the [DCs] pulsed with peptide, and this difference was statistically significant"
You can read that as:
'overall survival in the DCVax-L-like group is longer than in the ICT-107-like group'

I'm only saying that it validates the concept previously presented both on this forum and by nwbo management (and on SA and in commentary in a bunch of other places) that the broad-spectrum naturally-identical antigen presentation which comes from using *autologous whole tumor lysate* versus *synthetic peptides from 6 tumor-stem cell associated antigens* is a significant (and apparently positive) difference. This is contrary to the assertions of some other commentators that synthetic fragments weren't a problem and picking six common antigens was as good as automatically getting exposed to all of them (and implying therefore that ICT-107's failure necessarily predicts DCVax-L's ultimate fate).